Patents by Inventor Andre Giroux

Andre Giroux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cytomegalovirus inhibitor compounds
    Patent number: 9315499
    Abstract: Compounds of Formula (I) wherein n, m, R1, R2, R3, R4, R5 and R6 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.
    Type: Grant
    Filed: April 3, 2013
    Date of Patent: April 19, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Lee Fader, Olivier Lepage, Murray Bailey, Pierre Louis Beaulieu, Francois Bilodeau, Rebekah J. Carson, André Giroux, Cédrickx Godbout, Benoît Moreau, Julie Naud, Mathieu Parisien, Martin Poirier, Maude Poirier, Simon Surprenant, Carl Thibeault
  • Cytomegalovirus inhibitor compounds
    Patent number: 9249158
    Abstract: Compounds of Formula (I) wherein n, A, R1, R2, R3 and R5 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.
    Type: Grant
    Filed: April 3, 2013
    Date of Patent: February 2, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Lee Fader, Pierre Louis Beaulieu, Murray Bailey, Francois Bilodeau, Rebekah J. Carson, André Giroux, Cédrickx Godbout, Oliver Hucke, Marc-André Joly, Mélissa Leblanc, Olivier Lepage, Benoit Moreau, Julie Naud, Martin Poirier, Elisia Villemure
  • HIV protease inhibitors
    Patent number: 9133157
    Abstract: Compounds of Formula I are disclosed: wherein A, R1, R2, R3, R4A, R4B, R5, R6 and R7 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: September 15, 2015
    Assignee: Merck Canada Inc.
    Inventors: Michael John Boyd, Jean-Francois Chiasson, Sheldon Crane, André Giroux
  • CYTOMEGALOVIRUS INHIBITOR COMPOUNDS
    Publication number: 20150158861
    Abstract: Compounds of Formula (I) wherein n, m, R1, R2, R3, R4, R5 and R6 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.
    Type: Application
    Filed: April 3, 2013
    Publication date: June 11, 2015
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Lee Fader, Olivier Lepage, Murray Bailey, Pierre Louis Beaulieu, Francois Bilodeau, Rebekah J. Carson, André Giroux, Cédrickx Godbout, Benoît Moreau, Julie Naud, Mathieu Parisien, Martin Poirier, Maude Poirier, Simon Surprenant, Carl Thibeault
  • CYTOMEGALOVIRUS INHIBITOR COMPOUNDS
    Publication number: 20150080366
    Abstract: Compounds of Formula (I) wherein n, A, R1, R2, R3 and R5 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.
    Type: Application
    Filed: April 3, 2013
    Publication date: March 19, 2015
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Lee Fader, Pierre Louis Beaulieu, Murray Bailey, Francois Bilodeau, Rebekah J. Carson, André Giroux, Cédrickx Godbout, Oliver Hucke, Marc-André Joly, Mélissa Leblanc, Olivier Lepage, Benoit Moreau, Julie Naud, Martin Poirier, Elisia Villemure
  • HIV PROTEASE INHIBITORS
    Publication number: 20140303171
    Abstract: Compounds of Formula I are disclosed: wherein A, R1, R2, R3, R4A, R4B, R5, R6 and R7 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: October 26, 2012
    Publication date: October 9, 2014
    Inventors: Michael John Boyd, Jean-Francois Chiasson, Sheldon Crane, André Giroux
  • 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
    Patent number: 7943649
    Abstract: The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: May 17, 2011
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Anh Chau, Bernard Cote, Yves Ducharme, Richard Frenette, Richard Friesen, Marc Gagnon, Andre Giroux, Evelyn Martins, Hongping Yu, Tom Wu
  • 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles
    Publication number: 20090286772
    Abstract: The invention encompasses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.
    Type: Application
    Filed: February 22, 2007
    Publication date: November 19, 2009
    Inventors: Anh Chau, Bernard Cote, Yves Ducharme, Richard Frenette, Richard Friesen, Marc Gagnon, Andre Giroux, Evelyn Martins, Hongping Yu, Pierre Hamel
  • Phenanthrene derivatives as MPGES-1 inhibitors
    Publication number: 20090209571
    Abstract: The invention encompasses novel compounds of Formula or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.
    Type: Application
    Filed: May 15, 2007
    Publication date: August 20, 2009
    Inventors: Bernard Cote, Yves Ducharme, Richard Frenette, Richard Friesen, Andre Giroux, Evelyn Martins, Pierre Hamel
  • 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
    Publication number: 20090075998
    Abstract: The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.
    Type: Application
    Filed: October 24, 2008
    Publication date: March 19, 2009
    Inventors: Anh Chau, Bernard Cote, Yves Ducharme, Richard Frenette, Richard Friesen, Marc Gagnon, Andre Giroux, Evelyn Martins, Hongping Yu, Tom Wu
  • 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
    Patent number: 7442716
    Abstract: The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.
    Type: Grant
    Filed: November 23, 2005
    Date of Patent: October 28, 2008
    Assignee: Merck Frosst Canada Ltd.
    Inventors: Anh Chau, Bernard Cote, Yves Ducharme, Richard Frenette, Richard Friesen, Marc Gagnon, Andre Giroux, Evelyn Martins, Hongping Yu, Tom Wu
  • 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
    Publication number: 20070208017
    Abstract: The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.
    Type: Application
    Filed: November 23, 2005
    Publication date: September 6, 2007
    Inventors: Anh Chau, Bernard Cote, Yves Ducharme, Richard Frenette, Richard Friesen, Marc Gagnon, Andre Giroux, Evelyn Martins, Hongping Yu, Tom Wu
  • Irreversible caspase-3 inhibitors as active site probes
    Publication number: 20060069038
    Abstract: The present invention encompasses a compound of Formula (I) useful as caspase active site probes. These probes can be used to determine whether a caspase has been activated, in cells or in tissues of animal models of various pathologies. Furthermore, through competition based assays, these caspase active site probes can be used to calculate the percentage of occupancy of active caspases by other, unlabeled inhibitors.
    Type: Application
    Filed: February 5, 2004
    Publication date: March 30, 2006
    Inventors: John Colucci, Andre Giroux, Yongxin Han, Nathalie Methot, Donald Nicholson, Sophie Roy, John Vaillancourt, Paul Tawa
  • Pyrazinones, compositions containing such compounds and methods of use
    Patent number: 6699856
    Abstract: Compounds represented by formula I: as well as pharmaceutically acceptable salts, esters, N-oxides and hydrates thereof are disclosed. Pharmaceutical compositions and methods of use are also included. The compounds are active against the caspase-3 enzyme, and thus are useful to treat caspase-3 mediated diseases and conditions.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: March 2, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Yongxin Han, Andre Giroux, Robert Zamboni, Daniel J. McKay, Christopher I. Bayly, Erich L. Grimm, John Colucci
  • Pyrazinones, compositions containing such compounds and methods of use
    Publication number: 20030236402
    Abstract: Compounds represented by formula I: 1
    Type: Application
    Filed: July 25, 2002
    Publication date: December 25, 2003
    Applicant: Merck Frosst Canada & Co.
    Inventors: Yongxin Han, Andre Giroux, Robert Zamboni, Daniel J. McKay, Christopher I. Bayly, Erich L. Grimm, John Colucci
  • Gamma-ketoacid dipeptide derivatives as inhibitors of caspase-3
    Publication number: 20030045478
    Abstract: This invention encompasses the novel compounds of Formula I, which are useful in the treatment of caspase-3 mediated diseases.
    Type: Application
    Filed: December 14, 2001
    Publication date: March 6, 2003
    Inventors: Yongxin Han, Renee Aspiotis, Andre Giroux, Erich L. Grimm, Christophe Mellon, Robert Zamboni, Christopher I. Bayly
  • Gamma-ketoacid dipeptides as inhibitors of caspase-3
    Patent number: 6525025
    Abstract: This invention encompasses the novel compounds of Formula I, which are useful in the treatment of caspase-3 mediated diseases. The invention also encompasses certain pharmaceutical compositions comprising compounds of Formula I as well as methods for treatment of caspase-3 mediated diseases.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: February 25, 2003
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yongxin Han, Andre Giroux, Erich L. Grimm, Renee Aspiotis, Cameron Black
  • Gamma-ketoacid dipeptides as inhibitors of caspase-3
    Publication number: 20020165230
    Abstract: This invention encompasses the novel compounds of Formula I, which are useful in the treatment of caspase-3 mediated diseases.
    Type: Application
    Filed: September 7, 2001
    Publication date: November 7, 2002
    Inventors: Yongxin Han, Andre Giroux, Erich L. Grimm, Renee Aspiotis, Cameron Black
  • Pyrazinones, compositions containing such compounds and methods of use
    Patent number: 6444811
    Abstract: Compounds represented by formula I: as well as pharmaceutically acceptable salts, esters, N-oxides and hydrates thereof are disclosed. Pharmaceutical compositions and methods of use are also included. The compounds are active against the caspase-3 enzyme, and thus are useful to treat fin caspase-3 mediated diseases and conditions.
    Type: Grant
    Filed: July 19, 2000
    Date of Patent: September 3, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Yongxin Han, Andre Giroux, Robert Zamboni, Daniel J. McKay, Christopher I. Bayly, Erich L. Grimm, John Colucci
  • Gamma-ketoacid dipeptides as inhibitors of caspase-3
    Patent number: 6225288
    Abstract: Compounds represented by formula I: as well as pharmaceutically acceptable salts, esters and hydrates thereof are disclosed along with pharmaceutical compositions and methods of treatment. The compounds are useful as inhibitors of caspase-3, which is implicated in modulating apoptosis.
    Type: Grant
    Filed: March 16, 2000
    Date of Patent: May 1, 2001
    Assignee: Merk Frosst Canada & Co.
    Inventors: Yongxin Han, Andre Giroux, Erich Grimm, Renee Aspiotis, Sebastien Francoeur, Robert Zamboni, Petpiboon Prasit, Christopher Bayly, Dan McKay, Cameron Black